Abstract: Provided herein are compositions and methods that improve cognition in individuals having or at risk of having Alzheimers disease, including familial Alzheimers disease, early-onset Alzheimers disease, and middle to late stage Alzheimers disease.

Abstract: The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.

Abstract: The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.

Abstract: Described herein are compositions and methods for treating cancer and autoimmune diseases.

Abstract: Disclosed herein is a rodent and human behavioral test for evaluating visual dysfunctions associated with the retinal changes in Alzheimer disease progression. In one example, the inventors developed a maze that tests rodent's ability to identify (1) specific contrasts, (2) specific colors, (3) certain items in the visual field, and (4) other ‘non-typical’ peripheral and night vision functions associated with AD. For instance, the inventors developed a maze the tests the rodents ability to avoid certain colors or contrasts gradients. The maze may include certain rooms with specific visual markers (e.g., colors, contrasts, objects or other visual features) that also contain shock plates.

Abstract: The present invention describes a method for the detection, diagnosis and monitoring of cognitive impairment and Alzheimer's disease. The method involves the detection of pericyte loss and deficiency in PDGFR?, alone or in combination with retinal vascular A? deposits. The method also involves detecting an alteration in blood-retinal barrier (BRB) cell tight junction.

Abstract: The present invention describes a method of treating, preventing, reducing the likelihood of or alleviating a symptom of Alzheimer's disease and associated conditions by increasing OPN expression. The invention further provides for a method of improving cognitive function in a subject in need thereof.

Abstract: The invention provides a nanovehicle, comprising: a core, wherein the core comprises at least one iron oxide: a shell surrounding the core, wherein the shell comprises at least one polymer; and at least one boron cluster. The invention provides a method of treating a disease, disorder, or disease condition in a subject, comprising administering a therapeutically effective amount of the nanovehicle to the subject; and radiating the nanovehicle with neutrons. In various embodiments, the invention provides a method for detecting a cancer in a subject, comprising administering an effective amount of at least one nanoparticle of the present invention to the subject. The invention also provides the nanovehicles (e.g., nanoparticles) described herein in the form of various pharmaceutical formulations. The invention provides a kit, the kit comprises: a quantity of the nanovehicle (e.g., nanoparticle) described herein.

Abstract: The present invention provides a nanoparticle, comprising: a core, wherein the core comprises at least one iron oxide; a shell surrounding the core, wherein the shell comprises at least one polymer; and at least one targeting moiety attached to the shell, wherein the nanoparticle does not comprise boron, for use in methods for detecting and treating cancer in a subject.

Abstract: Mini nanodrugs that include a polymalic-based molecular scaffold with one or more peptides capable of crossing the blood-brain barrier, one or more plaque-binding peptides and one or more therapeutic agents attached to the scaffold are provided. Methods of treating brain diseases or abnormal conditions, and imaging of the same in a subject by administering the mini nanodrugs are described. Methods for reducing formation of amyloid plaques in the brain of a subject are disclosed.

Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.

Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.

Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.

Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.

Abstract: Disclosed herein is a rodent and human behavioral test for evaluating visual dysfunctions associated with the retinal changes in Alzheimer disease progression. In one example, the inventors developed a maze that tests rodent's ability to identify (1) specific contrasts, (2) specific colors, (3) certain items in the visual field, and (4) other ‘non-typical’ peripheral and night vision functions associated with AD. For instance, the inventors developed a maze the tests the rodents ability to avoid certain colors or contrasts gradients. The maze may include certain rooms with specific visual markers (e.g., colors, contrasts, objects or other visual features) that also contain shock plates.

Abstract: Imaging nanoagents including a polymalic acid-based molecular scaffold, a chlorotoxin peptide or a variant thereof, and at least one fluorescent moiety are provided. Methods for detecting, treating and removing a cancer in a subject by administering the imaging nanoagent are described.

Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.

Abstract: Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.

Abstract: Described herein are methods and systems for analyzing a sample by applying time resolved laser induced fluorescence spectroscopy to the sample to measure lifetime time decay profile data relating to the sample, and applying multivariate analysis to process the data so as to classify a sample as, for example, normal or abnormal. The sample may be cells, fluid or tissue from any organ. The sample may be in vitro or in vivo. The data may be obtained in situ or in vitro.

Abstract: The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. A?-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.